Vnitr Lek 2023, 69(5):312-315 | DOI: 10.36290/vnl.2023.061

Differentiated thyroid cancer - possible risks of treatment, suppressive therapy and adherence to current recommendations

Petra Němčíková1, 2, Ludmila Brunerová1, 3
1 3. lékařská fakulta Univerzity Karlovy, Praha
2 Oddělení nukleární medicíny Nemocnice České Budějovice
3 Interní klinika FNKV a 3. LF UK Praha

Thyroid carcinoma (TC) is rare and represents 1-2 % of all human tumors. The incidence of TC has been increasing worldwide. TC comprises of a heterogeneous group of tumours with variable biological activity. Women are mostly affected. TC can be divided in differentiated TC/DTCs (papillary - PTC, follicular - FTC, from Hürthle cells - HCC), medullary carcinoma - MTC and anaplastic thyroid cancer - ATC. In this article, we focus on possible pitfalls of suppression therapy (cardiovascular, bone and mental), particularly in low-risk patients, and we discuss the data on the adherence to guidelines for suppression therapy in DTC.

Keywords: differentiated thyroid cancer, supression therapy, adherence, risks.

Accepted: August 24, 2023; Published: September 12, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Němčíková P, Brunerová L. Differentiated thyroid cancer - possible risks of treatment, suppressive therapy and adherence to current recommendations. Vnitr Lek. 2023;69(5):312-315. doi: 10.36290/vnl.2023.061.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Epidemiologie zhoubných nádorů data z roku 2021. Available from: www: .
    2. Ahn HS, Kim HJ, Kim KH, et al. Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid. 2016;26(11):1535-1540. Go to original source... Go to PubMed...
    3. Fagin JA, Wells SA. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(11):1054-1067. Go to original source... Go to PubMed...
    4. Vlček P, Nováková D, Katra R. Karcinomy štítné žlázy: současný pohled na diagnostiku a léčbu. Vnitr Lek. 2017;63(9):572-579. Go to original source... Go to PubMed...
    5. Brierley JD (ed.), Gospodarowicz MK (ed.), Wittekind Ch (ed). TNM Classification of Malignant Tumours, 8th Edition. Wiley­‑Blackwell 2016. ISBN 978-1-119-26357-9. Available from: .
    6. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. Go to original source... Go to PubMed...
    7. Haddad R.I. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Thyroid Carcinoma. NCCN; Plymouth, PA, USA 2023. Available from:
    8. Bernardi S, Palermo A, Grasso RF, et al. Current Status and Challenges of US­‑Guided Radiofrequency Ablation of Thyroid Nodules in the Long Term: A Systematic Review. Cancers (Basel) 2021;13(11):2746. Go to original source... Go to PubMed...
    9. Avram AM, Giovanella L, Greenspan B, et al. SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version. J Nucl Med. 2022,63(6):15N-35N.
    10. Sawin CT, Geller A, Wolf P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrilation in older persons. N Engl J Med. 1994;331(19):1249-1952. Go to original source... Go to PubMed...
    11. Ochs N, Auer R, Bauer DC et al. Metaanalysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008;148(11):832-845. Go to original source...
    12. Quan ML, Pasieka JL, Rorstad O. Bone mineral density in well­‑differentiated thyroid cancer patients treated with suppressive thyroxine: A systematic overview of the literature. J Surg Oncol. 2002;79(1):62-70. Go to original source... Go to PubMed...
    13. Ran B, Wei F, Gong J, Xu H, et al. Application and prospect of trabecular bone score in differentiated thyroid cancer patients receiving thyrotropin suppression therapy. Front Endocrinol (Lausanne). 2022 Oct 12;13:1004962. doi: 10.3389/fendo.2022.1004962 Go to original source... Go to PubMed...
    14. Ku EJ, Yoo WS, Lee EK, et al. Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta­‑analysis. J Clin Endocrinol Metab. 2021;106(12):3655-3667. Go to original source...
    15. Park H, Park J, Yoo H, et al. Bone­‑density testing interval and transition to osteoporosis in differentiated thyroid carcinoma patients on TSH suppression therapy. Clin Endocrinol (Oxf) 2022;97(1):130-136. Go to original source... Go to PubMed...
    16. Gülsoy Kirnap N, Turhan Iyidir Ö, Bozkuş Y, et al. The effect of iatrogenic subclinical hyperthyroidism on anxiety, depression and quality of life in differentiated thyroid carcinoma. Turk J Med Sci. 2020;50(4):870-876. Go to original source...
    17. Altuntaş SÇ, Hocaoğlu Ç. Effects of Chronic Suppression or Oversuppression of Thyroid­‑Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer. Horm Metab Res. 2021;53(10):683-691. Go to original source...
    18. Papaleontiou M, Chen DW, Banerjee M. et al. Thyrotropin Suppression for Papillary Thyroid Cancer: A Physician Survey Study. Thyroid. 2021;31(9):1383-1390. Go to original source... Go to PubMed...
    19. Yavuz DG, Yazan CD, Hekimsoy Z, et al. Assesment of attainment of recommended TSH levels and levothyroxine compliance in differentiated thyroid cancer patients. Clin Endocrinol (Oxf) 2022;97(6):833-840. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.